Cardioxane—ICRF-187 towards anticancer drug specificity through selective toxicity reduction
- 1 March 1991
- journal article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 18 (1) , 1-19
- https://doi.org/10.1016/0305-7372(91)90002-h
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive ratsCancer Chemotherapy and Pharmacology, 1989
- The interaction of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycinInflammation Research, 1989
- Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) ratsToxicology and Applied Pharmacology, 1988
- Amelioration of chronic anthracycline cardiotoxicity by ICRF-187 and other compoundsCancer Treatment Reviews, 1987
- ICRF-187Drugs of the Future, 1987
- Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbitsCancer Chemotherapy and Pharmacology, 1986
- Determination of razoxane by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1983
- Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancyCancer, 1981
- Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor ResponseScience, 1977
- Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high-dosage scheduleCancer, 1974